IMV Announces Finalization of the Basket Clinical Study in Collaboration With Merck and Reveals Promising Top Line Data From the Bladder and MSI-High Cohorts

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S, previously known as DPX-Survivac) in combination with Merck’s KEYTRUDA® in patients with metastatic bladder and Micro-Satellite Instability High (MSI-H) solid tumors. Read More